<DOC>
	<DOCNO>NCT02360423</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy deliverability CRE8 sirolimus-eluting stent RESOLUTE zotarolimus-eluting stent treatment patient de novo coronary artery lesion .</brief_summary>
	<brief_title>Safety Efficacy CRE8 Stent Treatment De Novo Coronary Artery Lesions</brief_title>
	<detailed_description>This study consist randomize controlled cohort long stent observational cohort . The randomized controlled trial prospective , multi-center , non-inferior , randomize control trial . The control device ( RESOLUTE zotarolimus-eluting stent ) use trial provide Medtronic . RESOLUTE zotarolimus-eluting stent already approve China Food Drug Administration ( CFDA ) 2009 become commercially available Chinese market . 400 patient enrolled trial randomly assign CRE8 group ( n=200 ) RESOLUTE group ( n=200 ) 1:1 ratio . The long stent observational trial plan enroll 30 consecutive patient . Patients observational cohort receive long CRE8 stent length 38mm.All 430 patient require receive clinical follow-up 1 month , 6 month , 9 month , 12 month annually 5 year procedure , angiographic follow-up 9 month procedure . The primary endpoint in-stent LLL 9 month procedure , secondary endpoint device success rate , device-oriented cardiovascular composite endpoint , patient-oriented cardiovascular composite endpoint stent thrombosis .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criterion randomize cohort : Age ≥18 year ≤ 75 year , male female without pregnancy ; Patients clinical evidence asymptomatic heart disease , stable unstable angina , old myocardial infarction ; De novo lesion native coronary artery ( lesion number ≤ 2 ) ; Target vessel diameter 2.25 4.0 mm target lesion length ≤ 27mm visual estimation ; Target lesion diameter stenosis ≥ 70 % visual estimation ; Each target lesion permit implant one stent , except bailout stent ; Patients eligible percutaneous coronary intervention ( PCI ) acceptable candidate surgical revascularization ( CABG ) ; Patients leave ventricular ejection fraction ≥40 % ; Patients understand nature study , agree participate accept angiographic clinical followup , provide write informed consent . Inclusion criterion long stent observational cohort : Age ≥18 year ≤ 75 year , male female without pregnancy ; Patients clinical evidence asymptomatic heart disease , stable unstable angina , old myocardial infarction ; De novo lesion native coronary artery ( lesion number ≤ 2 ) ; Target lesion diameter stenosis ≥ 70 % visual estimation ; At least one target lesion reference vessel diameter 2.5mm 4.0mm require 38mm stent exists ; Patients eligible percutaneous coronary intervention ( PCI ) acceptable candidate surgical revascularization ( CABG ) ; Patients leave ventricular ejection fraction ≥40 % ; Patients understand nature study , agree participate accept angiographic clinical followup , provide write informed consent . Patients acute myocardial infarction ( AMI ) within one week ; Chronic total occlusion lesion ( TIMI flow 0 procedure ) , Left main disease and/or triplevessel lesion might require treatment , bifurcation lesion side branch diameter &gt; 2.5mm graft lesion ; Heavily calcify tortuous lesion successfully predilated , lesion suitable stent delivery deployment ; Instent restenosis ; Thrombotic lesion ; Patients receive stent past one year ; Patients acute chronic renal dysfunction ( define creatinine great 2.0 mg/dl ) ; Patients cardiogenic shock , acute infection , know bleed coagulation disorder , history active gastrointestinal bleeding , ulcer , cerebral hemorrhage subarachnoid hemorrhage stroke within 6 month ; Patients allergic aspirin , clopidogrel , ticagrelor , ticlopidine , heparin , contrast agent , sirolimus , zotarolimus , polymer , CoCr alloy , contraindication aspirin clopidogrel ticagrelor ; Patients life expectancy le 1year ; Patients participate another investigational drug device trial complete primary endpoint ; Patient opinion investigator , unable comply requirement study protocol ; Patients underwent heart transplant surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>